Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study)
Endocrinology and Metabolism · 30.06.2026 · 41 (3) · 393-404
DOI: 10.3803/enm.2025.2579 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Endocrinology and Metabolism, erschienen am 30.06.2026. Verfasst von Ji Yoon Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and ICT, Ministry of Trade, Industry and Energy, Ministry of Health and Welfare.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Stage 2 or 3 connected insulin pens (CIPs) refer to tracking insulin pens that are capable of transmitting insulin dose data via cloud connectivity. Stage 4 CIPs feature a bolus calculator that determines appropriate insulin doses based on real-time continuous glucose monitoring (CGM) data, carbohydrate intake, previous dosing history, and preset parameters. Stage 5 CIPs additionally offer advanced decision-support features, such as education modules and coaching. However, the efficacy and safety of stage 5 CIPs have not yet been established.
Methods
In this prospective, open-label, parallel-group, multicenter, randomized controlled trial, we will include adults aged ≥19 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Förderung
- Ministry of Science and ICT
- Ministry of Trade, Industry and Energy
- Ministry of Health and Welfare
- Ministry of Food and Drug Safety
Zitieren
APA
Kim, J. Y., Kim, N. H., Kwak, S. H., Jung, C. H., Kang, E. S., Moon, J. S., Moon, S. J., Kwon, S. Y., Yoo, J. H., Kim, Y., Lee, T. M., Yang, C. I., Kim, J. H., & Jin, S. M. (2026). Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study). Endocrinology and Metabolism, 41(3), 393-404. https://doi.org/10.3803/enm.2025.2579
Vancouver
Kim JY, Kim NH, Kwak SH, Jung CH, Kang ES, Moon JS, et al. Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study). Endocrinology and Metabolism. 2026;41(3):393-404. doi:10.3803/enm.2025.2579
BibTeX
@article{Kim2026,
author = {Kim, Ji Yoon and Kim, Nam Hoon and Kwak, Soo Heon and Jung, Chang Hee and Kang, Eun Seok and Moon, Jun Sung and Moon, Sun Joon and Kwon, So Yoon and Yoo, Jee Hee and Kim, Younghoon and Lee, Tae-Min and Yang, Chung-Il and Kim, Jae Hyeon and Jin, Sang-Man},
title = {Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study)},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {3},
pages = {393--404},
doi = {10.3803/enm.2025.2579}
}
EUVIMED